BR0207019A - Ligação de endotoxina através de bactérias de ácido láctico e bifidobactérias - Google Patents

Ligação de endotoxina através de bactérias de ácido láctico e bifidobactérias

Info

Publication number
BR0207019A
BR0207019A BR0207019-7A BR0207019A BR0207019A BR 0207019 A BR0207019 A BR 0207019A BR 0207019 A BR0207019 A BR 0207019A BR 0207019 A BR0207019 A BR 0207019A
Authority
BR
Brazil
Prior art keywords
bifidobacteria
lactic acid
acid bacteria
endotoxin binding
endotoxin
Prior art date
Application number
BR0207019-7A
Other languages
English (en)
Inventor
Eduardo Schiffrin
Guillermo Kociubinski
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8179863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0207019(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestle Sa filed Critical Nestle Sa
Publication of BR0207019A publication Critical patent/BR0207019A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/854—Lactobacillus acidophilus

Abstract

"LIGAçãO DE ENDOTOXINA ATRAVéS DE BACTéRIAS DE áCIDO LáCTICO E BIFIDOBACTéRIAS". A presente invenção refere-se ao uso de pelo menos uma cepa de bactérias de ácido láctico e/ou bifidobactérias tendo propriedades de superfície hidrofóbica para a preparação de uma composição pretendida para a prevenção ou para o tratamento de distúrbios mediados e/ou associados a endotoxina e composições alimentícias para seres humano e animais de estimação preparadas com ela.
BR0207019-7A 2001-02-06 2002-02-01 Ligação de endotoxina através de bactérias de ácido láctico e bifidobactérias BR0207019A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01200436 2001-02-06
PCT/EP2002/001163 WO2002062360A1 (en) 2001-02-06 2002-02-01 Endotoxin binding by lactic acid bacteria and bifidobacteria

Publications (1)

Publication Number Publication Date
BR0207019A true BR0207019A (pt) 2004-02-25

Family

ID=8179863

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207019-7A BR0207019A (pt) 2001-02-06 2002-02-01 Ligação de endotoxina através de bactérias de ácido láctico e bifidobactérias

Country Status (21)

Country Link
US (2) US7550285B2 (pt)
EP (1) EP1359924B1 (pt)
JP (3) JP2004531477A (pt)
KR (1) KR100845456B1 (pt)
CN (1) CN1250232C (pt)
AT (1) ATE375164T1 (pt)
AU (1) AU2002250886B2 (pt)
BR (1) BR0207019A (pt)
CA (1) CA2436264C (pt)
DE (1) DE60222856T2 (pt)
EA (1) EA006397B1 (pt)
ES (1) ES2292744T3 (pt)
HK (1) HK1066174A1 (pt)
IL (1) IL157071A0 (pt)
MX (1) MXPA03007024A (pt)
NO (1) NO20033372D0 (pt)
NZ (1) NZ527493A (pt)
PL (1) PL367083A1 (pt)
PT (1) PT1359924E (pt)
WO (1) WO2002062360A1 (pt)
ZA (1) ZA200306935B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2436264C (en) * 2001-02-06 2014-01-28 Societe Des Produits Nestle S.A. Endotoxin binding by lactic acid bacteria and bifidobacteria
FR2848115B1 (fr) * 2002-12-05 2005-03-25 Rhodia Chimie Sa Composition de bacteries et son utilisation
SE526711C2 (sv) 2003-01-31 2005-10-25 Probi Ab Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
PL1885383T3 (pl) 2005-05-31 2017-06-30 Iams Europe B.V. Kocie probiotyczne bifidobakterie
WO2006130187A1 (en) 2005-05-31 2006-12-07 The Iams Company Feline probiotic lactobacilli
US20090083067A1 (en) * 2006-03-29 2009-03-26 Mary Elaine Freeland Methods and kits for selecting a health care product
BRPI0808391A2 (pt) 2007-02-01 2014-07-08 Lams Company Método para diminuir a inflamação e o estresse em um mamífero, mediante o uso de antimetabólitos de glicose, abacate ou extratos de abacate.
BRPI0808145A2 (pt) * 2007-02-28 2021-03-23 Mead Johnson Nutrition Company Produto contendo probiótico inativado para crianças ou lactentes.
KR100913406B1 (ko) * 2008-03-25 2009-08-21 광주과학기술원 Ｔｈ１－매개 면역 질환의 예방 또는 치료용 조성물
US9771199B2 (en) * 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US9232813B2 (en) * 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
DK2459203T3 (en) * 2009-07-30 2019-02-18 Dupont Nutrition Biosci Aps Lactic Acid Bacteria and Bifidobacteria for the Treatment of Endotoxemia
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
WO2011069860A1 (en) 2009-12-08 2011-06-16 Chr. Hansen A/S Novel use for the treatment of metabolic endotoxemia
JP2010280664A (ja) * 2010-07-02 2010-12-16 Biogaia Ab ラクトバチルス・リューテリ（Ｌａｃｔｏｂａｃｉｌｌｕｓｒｅｕｔｅｒｉ）株を用いる哺乳類における免疫機能の改善方法
CN103781368A (zh) 2011-07-13 2014-05-07 弗里斯兰品牌有限公司 具有低lps的乳品类组合物
US20130022586A1 (en) * 2011-07-21 2013-01-24 James Versalovic Production and use of bacterial histamine
US9173910B2 (en) 2012-02-29 2015-11-03 The General Hospital Corporation Compositions of microbiota and methods related thereto
CA2923236C (en) * 2013-09-30 2019-06-04 Elc Management Llc Watery lotion skin care compositions and methods
EP3212001A4 (en) 2014-10-31 2018-04-25 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
CN104498375B (zh) * 2014-12-02 2017-05-10 江南大学 一株具有内毒素吸附特性的耶氏酵母及其吸附特性研究方法
JP6710075B2 (ja) * 2016-03-29 2020-06-17 カゴメ株式会社 Ｌｐｓ産生抑制剤、及びｌｐｓ産生抑制用の食品組成物
TWI640319B (zh) * 2017-05-12 2018-11-11 健茂生物科技股份有限公司 具有抗發炎活性之醱酵液的製備方法
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
JP6888145B2 (ja) * 2020-03-23 2021-06-16 カゴメ株式会社 Ｌｐｓ産生抑制剤、及びｌｐｓ産生抑制用の食品組成物
US20230210964A1 (en) * 2020-06-07 2023-07-06 Sundaram Ramasamy Compositions and methods for detoxifying bacterial endotoxins and hydrogen sulfide by recombinant fusion enzymes
US20230323332A1 (en) 2020-08-28 2023-10-12 Chr. Hansen A/S Microencapsulation of microbial culture using octenyl succinic anhydride starch-chitosan complex coacervate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US555618A (en) * 1896-03-03 Hay-loader
IT1254210B (it) * 1992-02-10 1995-09-14 Simone Claudio De Composizioni dietetiche e/o farmaceutiche a base di batteri lattici liofilizzati, loro preparazione e impiego
US5413785A (en) * 1993-01-27 1995-05-09 New England Deaconess Hospital Corp. Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo
JP2506314B2 (ja) * 1993-10-27 1996-06-12 全国農業協同組合連合会 家禽・豚の敗血症の予防・治療剤及び飼料
US6506389B2 (en) * 1995-10-20 2003-01-14 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek (Tno) Adherence factors of non pathogenic microorganisms and applications thereof for screening microorganisms for specific probiotic properties; novel pharmaceutical compositions and food additives comprising such microorganisms and adherence factors
EP0862863B9 (en) * 1997-01-09 2009-08-12 Societe Des Produits Nestle S.A. Cereal product containing probiotics
JP4163276B2 (ja) * 1998-02-05 2008-10-08 独立行政法人理化学研究所 機能性組成物
US6368591B2 (en) 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
JP2003522731A (ja) * 1998-12-11 2003-07-29 ウレックス バイオテック インク． 泌尿生殖器感染に対する処置および防止のための乳酸菌の経口投与方法
PL358214A1 (en) * 2000-03-24 2004-08-09 Societe Des Produits Nestle S.A. Use of lactic acid bacterium for the treatment of peritonitis
CA2436264C (en) * 2001-02-06 2014-01-28 Societe Des Produits Nestle S.A. Endotoxin binding by lactic acid bacteria and bifidobacteria

Also Published As

Publication number Publication date
CN1501805A (zh) 2004-06-02
US20040115178A1 (en) 2004-06-17
EP1359924B1 (en) 2007-10-10
JP2004531477A (ja) 2004-10-14
IL157071A0 (en) 2004-02-08
MXPA03007024A (es) 2003-11-18
KR20030076652A (ko) 2003-09-26
EP1359924A1 (en) 2003-11-12
US20100136662A1 (en) 2010-06-03
CA2436264A1 (en) 2002-08-15
HK1066174A1 (en) 2005-03-18
JP2011246483A (ja) 2011-12-08
NO20033372L (no) 2003-07-28
DE60222856T2 (de) 2008-07-24
DE60222856D1 (de) 2007-11-22
CA2436264C (en) 2014-01-28
EA200300862A1 (ru) 2003-12-25
CN1250232C (zh) 2006-04-12
US7550285B2 (en) 2009-06-23
JP5973701B2 (ja) 2016-08-23
EA006397B1 (ru) 2005-12-29
ZA200306935B (en) 2004-12-06
ES2292744T3 (es) 2008-03-16
US7964384B2 (en) 2011-06-21
KR100845456B1 (ko) 2008-07-10
PT1359924E (pt) 2007-12-07
NO20033372D0 (no) 2003-07-28
AU2002250886B2 (en) 2007-08-02
PL367083A1 (en) 2005-02-21
ATE375164T1 (de) 2007-10-15
JP2014062104A (ja) 2014-04-10
NZ527493A (en) 2005-06-24
WO2002062360A1 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
BR0207019A (pt) Ligação de endotoxina através de bactérias de ácido láctico e bifidobactérias
WO2005055944A3 (en) Oligosaccharide compositions and use thereof in the treatment of infection
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
MXPA06000318A (es) Pano limpiador y metodos para mejorar la salud de la piel.
IL147271A0 (en) Compounds that bind her2
WO2005110445A3 (en) Methods and compositions for the dietary management of autoimmune disorders
BR0211888A (pt) Materiais e métodos para promoção de reparo de tecido nervoso
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
BR9916062A (pt) Administração oral de lactobacillus para o tratamento e prevenção de infecção urogenital
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2003099110A3 (en) Herbs and herbal combinations useful for the treatment of microbial infections
MY148286A (en) Freeze-dried, aerated dairy or dairy-substitute compositions and methods of making thereof
WO2006082328A3 (fr) Compositions comprenant des micro-organismes deshydrates, leurs procedes de preparation, et leurs utilisations
WO2006034001A3 (en) Methods of treating hiv infection
EP2772254A3 (en) Novel Antibacterial Agents
EP1800691A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
BR0314511A (pt) Seleção e uso de bactérias de ácido lático para reduzir a inflamação causada por helicobater
PT1328268E (pt) Combinacao de catequina e quercetina para utilizacao farmaceutica ou dietetica
WO2021004958A3 (en) Compositions comprising bacterial strains
PL346143A1 (en) Tan-1057 derivatives
BRPI0409609A (pt) mediadores do transporte reverso de colesterol para o tratamento da hipercolesterolemia
DE60235418D1 (de) Osteoprotegerin in Milch
WO2003026693A3 (en) Inhibitors of costimulation by 0x40 and their use against infectious diseases
WO2007058934A3 (en) Methods and compositions for treating basement membrane disorders

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.